

CareWell Health
Modern Slavery Statement
Calendar year 2023

Table of contents

Reporting entity	3
Structure, Operations and Supply Chains	3
The risks of modern slavery practices in the operations and supply chains of CareWell	4
The actions taken to assess and address those risks	4
How we assess the effectiveness of such actions	4
The process for consultation with any entities the reporting entity owns or controls.....	5
Approval	5

Reporting entity

The reporting entity is CareWell Health Pty Ltd (ABN 59 650 354 706) with a registered office address of 3/97 Banksia St, Botany NSW 2019.

This statement sets out the actions to be taken by CareWell to assess and address modern slavery risks in our operations and supply chains over the 2023 calendar year.

As CareWell's annual turnover is under \$100 million, this is a voluntary statement under the Modern Slavery Act 2018 (Cth).

Structure, Operations and Supply Chains

CareWell Health is privately held, Australian owned family company.

Established in 2004, CareWell designs, manufactures, installs, and maintains medical equipment for hospitals, and aged care facilities in Australia. The company is also a registered NDIS supplier of assistive technology.

Our products include medical beds and mattresses, overbed tables, patient trolleys, bed movers, patient transfer aids, and accessories. We also sell a wide range of furniture for hospitals and aged care facilities, including lounges, chairs and bedside cabinets.

CareWell is structured as a single operational entity with the following divisions:

- Sales
- Engineering and design
- Management and administration
- Installation and commissioning management (aged care)
- Project management (commercial and government)
- Construction and installation
- Maintenance and after sales service.

We contract with long term partners in Australia, China, Taiwan and Singapore for the manufacture of Carewell-designed beds and mattresses. We also purchase other medical equipment (overbed tables, bed movers, patient transfer aids, and accessories) from trusted suppliers in these countries.

A geographic segmentation of the supply chain for our products is as follows:

- 71%: Large manufacturers and suppliers in China, Taiwan and Singapore.
- 23%: Products manufactured in Australia, sourced from independent suppliers
- 6%: Office and warehouse supplies (stationery, furniture, shelving, forklifts)

The risks of modern slavery practices in the operations and supply chains of CareWell

CareWell Health has not identified any modern slavery practices in our operations and domestic supply chains, however we recognise there are risks in our overseas supply chain as most of our products, and those of other medical equipment companies, are manufactured in China.

The Global Slavery Index (GSI) found China has 5.8 million people living in modern slavery, the world's second largest absolute number behind India, although by prevalence (1 in 4000 people) China ranks 19 out of 27 countries in the region. China also sits well outside the top 10 highest risk countries for modern slavery.

The national government has introduced a national action plan to combat modern slavery, however the GSI ranked their efforts below most assessed countries in the region. GSI also found the government's response to be belied by state-imposed forced labour against some ethnic and religious groups.

CareWell has not identified any specific modern slavery risks with the medical equipment industry in China, or with our manufacturing contractors, however we recognise the need for the company to remain vigilant.

We consider the risk of modern slavery practices in our operations and domestic supply chain to be low given Australia's high ranking on the Global Slavery Index and because of how CareWell sources products and services from local suppliers.

The actions taken to assess and address those risks, including due diligence and remediation processes

CareWell approaches the task of assessing and addressing those risks by:

- Inspecting factories and suppliers: We meet with our manufacturing partners and inspect factories to observe their work practices and review their policies and supply chains. If a manufacturer is unable or unwilling to provide satisfactory access and information about their work practices, we cease to use them.
- Educating our suppliers and manufacturing partners about modern slavery risks and encouraging them to make their own commitments to identify and address any risks in their operations and supply chains.
- Educating relevant staff to identify and assess modern slavery risks as part of CareWell's staff training on ethical purchasing standards.
- Buying where possible from Australian suppliers that have made their own commitments to assess and address modern slavery risks in their operations and supply chains.

How we assess the effectiveness of such actions

CareWell will be conducting an annual review to assess the effectiveness of its actions and to inform what steps we need to take in the next reporting period.

As part of this we will:

- Review factory reports to ensure we are obtaining the necessary information to assess and address risks in our supply chain. We will also be conducting year-on-year comparisons with previous reports.
- Based on the factory reports and other information, prioritise scrutiny of manufacturers and suppliers we have determined present higher risks.
- Assess supplier awareness of the risks of modern slavery practices in their operations and supply chains. CareWell will require suppliers to make commitments on modern slavery and we will incorporate modern slavery clauses into supplier contracts.
- Audit how many staff have completed training on modern slavery and CareWell's ethical training standards.
- Develop processes for regular engagement with manufacturing partners and suppliers to discuss modern slavery risks.
- Liaise with industry groups to ensure CareWell remains up to date about industry leading practices to assess and address modern slavery risks.

The process for consultation with any entities the reporting entity owns or controls

This criterion is not applicable as CareWell does not own or control any entities.

Approval

This statement was approved by the CareWell Health board on 10 December 2022.

Nicholas Falinski

Nicholas Falinski

Chief Executive Officer and Director
CareWell Health Pty Ltd

15/12/2022